Employees: 3,494
Size Jinxin Fertility (1951.HK) is a Hong Kong Health Care company (Medical/Nursing Services) with a market value of $758M, the 650th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$2.25 on 18 Nov 2026.
Performance Over six months the shares fell 4.0%, against +0.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 6.5% over the last twelve months (peer median +5.2%); the operating margin is 11.4% (peer median 6.8%).
Valuation It trades at 23.1× forward earnings against a peer median of 19.6× (7th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.4 points below its cost of capital (9.7% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$3.05B | HK$2.87B | HK$3.05B | HK$3.08B | HK$2.75B |
| Revenue growth | — | -6% | -1% | +12% | — |
| Gross profit | HK$1.08B | HK$911M | HK$1.14B | HK$1.25B | HK$970M |
| EBITDA | HK$739M | HK$510M | HK$780M | HK$847M | HK$591M |
| Net income | HK$192M | -HK$1.06B | HK$307M | HK$381M | HK$141M |
| Free cash flow | HK$254M | HK$243M | HK$268M | HK$407M | -HK$527M |
| Capital expenditure | HK$267M | HK$287M | HK$284M | HK$192M | HK$1.12B |
| Total debt | n/a | HK$3.29B | HK$2.89B | HK$3.07B | HK$5.00B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1951.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.1% | -0.5% | 10th highest of 21 |
| 6-month return | -4.0% | +0.9% | 10th lowest of 21 |
| Distance from 52-week high | -15.5% | -27.3% | 5th highest of 21 |
| Revenue growth (TTM) | +6.5% | +5.2% | 10th highest of 21 |
| Operating margin | 11.4% | 6.8% | 9th highest of 21 |
| Forward P/E | 23.1× | 19.6× | 7th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 17.8% | 8.7% | 5th most demanding of 17 |
| Growth delivered (Del g) | +12.4% | +11.5% | 8th highest of 17 |
| Hurdle (Req g minus delivered) | +5.5 pp | -4.9 pp | 4th most demanding of 17 |
| ROIC minus cost of capital | -7.4 pp | +0.2 pp | 5th lowest of 20 |
| EV / EBITDA | 11.6× | 8.5× | 6th most expensive of 15 |
| Net debt / EBITDA | 3.4× | 1.6× | 3rd most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 23.1× | 17.8% | +12.4% |
| HK inno.N 195940.KS | South Korea | $783M | -28% | +7% | 12% | 12.3× | -4.7% | +12.2% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 5.9× | -19.6% | -4.0% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 48.8× | 36.6% | +31.6% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | n/a | n/a | n/a |
| Terveystalo Oy TTALO.HE | Finland | $832M | -26% | -8% | 8% | 10.7× | -5.1% | +5.3% |
| Thyrocare Technologies THYROCARE.NS | India | $858M | +7% | +22% | 26% | 36.0× | 28.5% | +10.9% |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 10.1× | 10.1% | +94.5% |
| BML 4694.T | Japan | $932M | +12% | +4% | 7% | 19.8× | -9.0% | +1.6% |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 25.3× | 13.3% | +14.4% |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | n/a | 16.8% | +25.2% |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% | +8.2% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | n/a | n/a | n/a |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | n/a | 5.9% | +3.2% |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | n/a | n/a | n/a |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |